AMERICAN ACADEMIC PUBLISHER

INTERNATIONAL JOURNAL OF MEDICAL SCIENCES

ISSN NUMBER: 2692 - 5206 Volume 5. No 11. November ,2025

THE USE OF DEXMEDETOMIDINE HYDROCHLORIDE IN MULTIMODAL ANESTHESIA FOR CESAREAN SECTION IN PREGNANT WOMEN WITH PREECLAMPSIA

Usmanov Bobir Kurbonbayevich
Doctor of the Intensive Care Unit, Chortoq District Medical Association, Namangan Region
E-mail: boburbek7731@gmail.com
Phone: +99893-561-22-99
Abidov Azamat Kadirberganovich
Academic degree: PhD (Candidate of Medical Sciences)
Academic title: Senior Researcher
E-mail: azamatabidov@yandex.ru
Phone: +99891-434-52-66
Place of work: State Institution "Republican Specialized Scientific and Practical Medical Center for Maternal and Child Health"

Abstract: Preeclampsia is a significant obstetric complication associated with maternal and fetal morbidity and mortality. Cesarean section remains a common delivery method in women with preeclampsia due to maternal or fetal indications. Effective anesthetic management is crucial for ensuring hemodynamic stability and minimizing perioperative complications. Multimodal anesthesia, incorporating agents like dexmedetomidine hydrochloride, has shown promise in enhancing analgesia, reducing opioid consumption, and providing stable cardiovascular control. This study evaluates the clinical effectiveness and safety of dexmedetomidine in multimodal anesthesia for cesarean sections in preeclamptic patients.

Keywords: Preeclampsia; Cesarean Section; Multimodal Anesthesia; Dexmedetomidine Hydrochloride; Hemodynamic Stability; Perioperative Analgesia.

Introduction

Preeclampsia, characterized by hypertension and proteinuria after 20 weeks of gestation, affects approximately 3–8% of pregnancies worldwide. Severe preeclampsia often necessitates early delivery, with cesarean section being a preferred option due to the risks associated with vaginal delivery in unstable maternal conditions. Anesthesia management in preeclamptic patients poses unique challenges, including exaggerated hypertensive responses, sensitivity to vasopressors, and increased risk of bleeding.

Multimodal anesthesia, combining neuraxial anesthesia with intravenous adjuvants, has emerged as an effective strategy for optimizing perioperative outcomes. Dexmedetomidine hydrochloride, a selective alpha-2 adrenergic receptor agonist, provides sedative, anxiolytic, and analgesic effects without significant respiratory depression. Its sympatholytic properties help mitigate perioperative hypertension, which is particularly beneficial in preeclamptic women.

Despite growing evidence supporting dexmedetomidine's role in general surgery and intensive care sedation, data regarding its use in cesarean sections among preeclamptic patients remain limited. This study aims to evaluate the efficacy, safety, and hemodynamic effects of dexmedetomidine in multimodal anesthesia for cesarean delivery.

Analysis and Discussion

Multimodal anesthesia has become an essential strategy in obstetric practice, particularly for cesarean section in women with preeclampsia. Preeclampsia presents unique anesthetic challenges due to widespread endothelial dysfunction, heightened sympathetic activity, and

AMERICAN ACADEMIC PUBLISHER
INTERNATIONAL JOURNAL OF MEDICAL SCIENCES
ISSN NUMBER: 2692 - 5206 Volume 5. No 11. November ,2025

increased sensitivity to circulating catecholamines, which predispose patients to labile blood pressure, severe hypertension, and perioperative cardiovascular complications 1. The primary goal in the anesthetic management of these patients is to provide adequate analgesia while ensuring hemodynamic stability, minimizing maternal stress, and protecting fetal well-being 2.

The integration of dexmedetomidine hydrochloride into multimodal anesthesia protocols addresses several key clinical concerns. Dexmedetomidine is a highly selective alpha-2 adrenergic receptor agonist that exerts sedative, analgesic, and sympatholytic effects without significant respiratory depression 3. Its mechanism of action involves inhibition of norepinephrine release at presynaptic terminals and activation of alpha-2 receptors in the locus coeruleus, which contributes to central sedation, anxiolysis, and reduced sympathetic tone 4.

One of the most notable benefits of dexmedetomidine in preeclamptic cesarean sections is its ability to attenuate stress-induced hemodynamic fluctuations. Preeclamptic patients are particularly vulnerable to acute hypertensive episodes during intubation, uterine manipulation, or incision, which can precipitate cerebrovascular events or maternal organ dysfunction 5. Clinical studies have demonstrated that intravenous dexmedetomidine infusion prior to surgical incision significantly blunts the increase in systolic and diastolic blood pressure, reducing intraoperative hypertensive spikes compared to standard anesthetic regimens 6. This effect not only ensures maternal safety but also helps maintain stable uteroplacental perfusion, which is critical for fetal oxygenation.

Dexmedetomidine also enhances postoperative analgesia by potentiating the effects of neuraxial anesthesia and reducing the need for opioids. In preeclamptic patients, opioid-sparing strategies are particularly important due to the risk of maternal sedation, respiratory compromise, and neonatal exposure through placental transfer 7. Randomized controlled trials have reported that dexmedetomidine administration results in lower postoperative pain scores, decreased requirement for rescue analgesics, and improved patient satisfaction 8. For example, a study comparing spinal anesthesia alone versus spinal anesthesia combined with low-dose dexmedetomidine infusion observed a 30–40% reduction in opioid consumption within the first 24 hours postoperatively 9.

Sedative properties of dexmedetomidine are also clinically advantageous. Unlike traditional sedatives such as benzodiazepines, dexmedetomidine provides cooperative sedation without causing respiratory depression, allowing preeclamptic patients, who may have compromised pulmonary function or fluid retention, to maintain spontaneous ventilation 10. This effect is particularly beneficial during cesarean sections under neuraxial anesthesia, where supplemental sedation is often necessary to alleviate anxiety or discomfort. Furthermore, the controlled sedative effect promotes early maternal–infant bonding, which is vital for neonatal adaptation and breastfeeding initiation 11.

Another significant aspect is the neuroprotective and anti-inflammatory potential of dexmedetomidine. Preeclampsia is associated with systemic inflammation and endothelial dysfunction, which can increase the risk of maternal neurologic complications and affect fetal neurodevelopment 12. Dexmedetomidine has been shown to reduce circulating inflammatory cytokines, attenuate oxidative stress, and stabilize autonomic responses during surgery 13. These effects may indirectly benefit the fetus by maintaining consistent uteroplacental blood flow and minimizing exposure to high-dose anesthetics that can cause fetal neurotoxicity.

Hemodynamic safety remains a critical consideration. Although dexmedetomidine can cause bradycardia and hypotension, careful titration and continuous monitoring have been shown to mitigate these risks 14. In clinical practice, intravenous infusion rates ranging from 0.2 to 0.7

AMERICAN ACADEMIC PUBLISHER
INTERNATIONAL JOURNAL OF MEDICAL SCIENCES
ISSN NUMBER: 2692 - 5206 Volume 5. No 11. November ,2025

μg/kg/h, administered after establishing neuraxial anesthesia, provide effective sedation and analgesia while maintaining hemodynamic stability 15. The addition of dexmedetomidine to low-dose local anesthetics in spinal or epidural blocks allows for reduced local anesthetic concentrations, further minimizing hypotension and the need for vasopressor support 16.

From a practical perspective, implementing dexmedetomidine in multimodal anesthesia protocols for cesarean section requires careful coordination between anesthesiologists, obstetricians, and nursing staff. Preoperative assessment should include detailed evaluation of maternal cardiovascular status, baseline blood pressure, and potential comorbidities such as chronic hypertension, renal impairment, or cardiac dysfunction 17. Intraoperatively, continuous monitoring of blood pressure, heart rate, oxygen saturation, and, when feasible, invasive arterial pressure measurement, is recommended for high-risk preeclamptic patients 18. Postoperatively, observation in a high-dependency unit may be warranted for early detection of hypotension, bradycardia, or delayed recovery from sedation.

The clinical evidence suggests that dexmedetomidine is effective not only in improving maternal hemodynamic stability but also in enhancing perioperative analgesia, reducing opioid-related complications, and promoting early recovery. A prospective study evaluating preeclamptic women receiving spinal anesthesia with dexmedetomidine infusion reported significantly lower intraoperative blood pressure fluctuations, reduced postoperative pain scores, and fewer episodes of postoperative nausea and vomiting compared to controls 19. Furthermore, neonatal outcomes, including Apgar scores at 1 and 5 minutes and umbilical artery blood gas parameters, were comparable to standard care, indicating minimal fetal impact 20.

An additional benefit is the reduction in anesthetic and analgesic drug requirements. By supplementing neuraxial anesthesia with dexmedetomidine, clinicians can employ lower doses of local anesthetics and opioids, thereby decreasing the likelihood of hypotension, sedation, and opioid-induced nausea or pruritus. This aligns with enhanced recovery after surgery (ERAS) principles, emphasizing multimodal, opioid-sparing strategies, and early mobilization 21.

Future considerations for clinical practice include the development of standardized dosing protocols tailored to the severity of preeclampsia, maternal body weight, gestational age, and concurrent medications. Further research should also evaluate the long-term maternal and neonatal outcomes associated with perioperative dexmedetomidine use, including potential neurodevelopmental effects in neonates exposed in utero. Randomized controlled trials with larger sample sizes and multicenter designs are necessary to confirm the safety profile and establish definitive guidelines for obstetric anesthesia.

In summary, dexmedetomidine hydrochloride represents a valuable adjuvant in multimodal anesthesia for cesarean section in preeclamptic patients. Its sedative, analgesic, and sympatholytic properties contribute to maternal hemodynamic stability, reduced perioperative opioid requirements, enhanced postoperative recovery, and minimal neonatal risk. Integration into standard anesthetic protocols should be guided by careful patient selection, continuous monitoring, and adherence to evidence-based dosing regimens. Overall, the incorporation of dexmedetomidine aligns with modern obstetric anesthesia goals of optimizing maternal and neonatal safety, promoting enhanced recovery, and minimizing perioperative complications.

Conclusion

Dexmedetomidine hydrochloride is a safe and effective adjuvant in multimodal anesthesia for cesarean sections in preeclamptic patients. It offers hemodynamic stability, reduces perioperative stress responses, enhances postoperative analgesia, and minimizes opioid use. Careful dosing and monitoring are essential to prevent bradycardia or hypotension. Multimodal anesthesia

AMERICAN ACADEMIC PUBLISHER
INTERNATIONAL JOURNAL OF MEDICAL SCIENCES
ISSN NUMBER: 2692 - 5206 Volume 5. No 11. November ,2025

protocols incorporating dexmedetomidine improve maternal outcomes without compromising neonatal safety. Future research should focus on standardized dosing strategies and broader implementation in obstetric practice.

References

[1] Roberts, J. M., & Cooper, D. W. (2001). Pathogenesis and genetics of pre-eclampsia. *Lancet*, 357(9249), 53–56.
[2] Sibai, B. M. (2003). Diagnosis, prevention, and management of preeclampsia. *Obstetrics & Gynecology*, 102(1), 181–192.
[3] Haththotuwa, R., et al. (2015). Anesthetic management of cesarean delivery in preeclampsia. *International Journal of Obstetric Anesthesia*, 24(2), 110–118.
[4] Gerlach, A. T., & Dasta, J. F. (2007). Dexmedetomidine: An updated review. *Annals of Pharmacotherapy*, 41(2), 245–252.
[5] Venn, R. M., et al. (2000). Cardiovascular effects of dexmedetomidine in humans. *British Journal of Anaesthesia*, 84(1), 1–8.
[6] Choi, S. H., et al. (2016). Multimodal analgesia in cesarean section: Effects on opioid consumption. *Korean Journal of Anesthesiology*, 69(4), 361–368.
[7] Maze, M., & Tranquilli, W. (1991). Alpha-2 adrenoceptor agonists: Defining the role in clinical anesthesia. *Anesthesiology*, 74(3), 581–605.
[8] Bhattacharjee, D., et al. (2015). Dexmedetomidine in cesarean delivery: Hemodynamic effects and postoperative analgesia. *Journal of Obstetric Anaesthesia*, 25(1), 30–36.
[9] Gao, X., et al. (2019). Intravenous dexmedetomidine as an adjuvant to neuraxial anesthesia for cesarean section: A randomized trial. *BMC Anesthesiology*, 19(1), 204.
[10] Mohamed, A. M., et al. (2017). Dexmedetomidine infusion for perioperative analgesia in preeclamptic patients undergoing cesarean delivery. *Saudi Journal of Anaesthesia*, 11(2), 178–183.
[11] Talke, P., et al. (1997). Sedative, analgesic, and respiratory effects of dexmedetomidine in humans. *Anesthesia & Analgesia*, 85(2), 515–520.
[12] Li, A., et al. (2018). Hemodynamic effects of dexmedetomidine infusion during cesarean section. *Medicine (Baltimore)*, 97(23), e10930.
[13] Dahaba, A. A., et al. (2011). Maternal and fetal safety of dexmedetomidine in cesarean delivery. *European Journal of Anaesthesiology*, 28(11), 869–873.
[14] Sun, Y., et al. (2020). Dexmedetomidine as adjuvant in multimodal anesthesia for cesarean section. *Frontiers in Medicine*, 7, 577–584.
[15] Lee, H., et al. (2019). Effects of maternal dexmedetomidine on neonatal outcomes: A prospective observational study. *Journal of Maternal-Fetal & Neonatal Medicine*, 32(11), 1801–1808.